CALL FOR PAPERS Regulation of Cardiovascular Functions by Eicosanoids and Other Lipid Mediators The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway

Kristina M. Fetalvero, Maureen Shyu, Athena P. Nomikos, Yuh-Fang Chiu, Robert J. Wagner, Richard J. Powell, John Hwa, and Kathleen A. Martin Department of Pharmacology and Toxicology, Dartmouth Medical School; and Department of Surgery, Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center; and Department of Medicine, Section of Cardiology, Dartmouth Medical School, Lebanon, New Hampshire

[1]  R. D. Rudic,et al.  COX-2–Derived Prostacyclin Modulates Vascular Remodeling , 2005, Circulation research.

[2]  Dairong Wang,et al.  Cardiovascular hazard and non-steroidal anti-inflammatory drugs. , 2005, Current opinion in pharmacology.

[3]  K. Martin,et al.  Endothelial cell activation of the smooth muscle cell phosphoinositide 3-kinase/Akt pathway promotes differentiation. , 2005, Journal of vascular surgery.

[4]  E. Puré,et al.  Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism , 2005, Circulation.

[5]  S. Narumiya,et al.  Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice , 2004 .

[6]  J. Hwa,et al.  Clusters of transmembrane residues are critical for human prostacyclin receptor activation. , 2004, Biochemistry.

[7]  G. Owens,et al.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease. , 2004, Physiological reviews.

[8]  D. Fingar,et al.  The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. , 2004, American journal of physiology. Cell physiology.

[9]  J. Vane,et al.  Prostacyclin: a vascular mediator. , 2003, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[10]  P. Stork,et al.  Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. , 2002, Trends in cell biology.

[11]  T. Grosser,et al.  Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.

[12]  E. Avvedimento,et al.  Membrane-bound cAMP-dependent Protein Kinase Controls cAMP-induced Differentiation in PC12 Cells* , 1999, The Journal of Biological Chemistry.

[13]  J. Balligand,et al.  Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. , 1999, The Journal of clinical investigation.

[14]  S. Narumiya,et al.  Prostanoid receptors: structures, properties, and functions. , 1999, Physiological reviews.

[15]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Sobue,et al.  Differentiated Phenotype of Smooth Muscle Cells Depends on Signaling Pathways through Insulin-like Growth Factors and Phosphatidylinositol 3-Kinase* , 1998, The Journal of Biological Chemistry.

[17]  S. Narumiya,et al.  Altered pain perception and inflammatory response in mice lacking prostacyclin receptor , 1997, Nature.

[18]  S. Bode-Böger,et al.  Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. , 1997, Circulation.

[19]  M. Fillinger,et al.  Coculture of endothelial cells and smooth muscle cells in bilayer and conditioned media models. , 1997, The Journal of surgical research.

[20]  G. Owens,et al.  Regulation of differentiation of vascular smooth muscle cells. , 1995, Physiological reviews.

[21]  Y. Boie,et al.  Cloning and expression of a cDNA for the human prostanoid IP receptor. , 1994, The Journal of biological chemistry.

[22]  M. Ferguson,et al.  Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. , 1993, Circulation research.

[23]  G. FitzGerald.  Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. , 1991, The American journal of cardiology.

[24]  J. Vane,et al.  Regulatory functions of the vascular endothelium. , 1990, The New England journal of medicine.

[25]  Y. Yazaki,et al.  Developmentally regulated expression of vascular smooth muscle myosin heavy chain isoforms. , 1989, The Journal of biological chemistry.

[26]  J. Vane,et al.  Mediators Produced by the Endothelial Cell , 1988, Hypertension.

[27]  C. Faul,et al.  Desensitization of platelets to iloprost. Loss of specific binding sites and heterologous desensitization of adenylate cyclase. , 1988, European journal of pharmacology.

[28]  G. Owens,et al.  Developmental changes in isoactin expression in rat aortic smooth muscle cells in vivo. Relationship between growth and cytodifferentiation. , 1986, The Journal of biological chemistry.

[29]  M. Caton,et al.  Prostaglandins and thromboxanes. , 1979, Progress in medicinal chemistry.

[30]  A. Daiber,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[31]  K. Sobue,et al.  Expressional regulation of smooth muscle cell-specific genes in association with phenotypic modulation , 2004, Molecular and Cellular Biochemistry.

[32]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[33]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors. , 2000, The Biochemical journal.

[34]  B. Samuelsson.  Prostaglandins and Thromboxanes , 1977, NATO Advanced Study Institutes Series.